Cazzola M, Matera M G, Santangelo G, Lampa E, Angrisani M, Loffreda A, Rossi F
Institute of Pharmacology and Toxicology, Faculty of Medicine and Surgery, Second University of Naples, Italy.
Int J Clin Pharmacol Res. 1993;13(2):69-73.
Antibiotics may interfere with platelet (PLT) function, and beta-lactam antibiotics may interact with PLT aggregation, by inhibiting the binding of agonists of this aggregation (such as ADP and collagen) to specific receptor sites. In this study we have evaluated the relative in-vitro antiplatelet effects of some old and new cephalosporins (cefonicid, ceftazidime, ceftriaxone, cefotaxime, cefuroxime and flomoxef) and of teicoplanin, a new glycopeptide antibiotic. All the cephalosporins tested, and also teicoplanin, were found to have the potential to adversely affect human platelet aggregation only at high concentrations which are not achieved in vivo.
抗生素可能会干扰血小板(PLT)功能,β-内酰胺类抗生素可能通过抑制血小板聚集激动剂(如ADP和胶原蛋白)与特定受体位点的结合来影响血小板聚集。在本研究中,我们评估了一些新旧头孢菌素(头孢尼西、头孢他啶、头孢曲松、头孢噻肟、头孢呋辛和氟氧头孢)以及新型糖肽类抗生素替考拉宁的相对体外抗血小板作用。所有测试的头孢菌素以及替考拉宁,均被发现仅在体内无法达到的高浓度下才有可能对人类血小板聚集产生不利影响。